Meropenem Eberth

Meropenem, the active ingredient in Meropenem Eberth, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, hospital‑acquired pneumonia, and meningitis in hospitalized patients.

GNH USA supplies Meropenem Eberth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections that require intravenous therapy. - Complicated intra‑abdominal infections: provides bacterial eradication in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: clears resistant Gram‑negative pathogens in the urinary tract. - Hospital‑acquired pneumonia: treats pneumonia caused by multidrug‑resistant organisms acquired in hospital settings. - Ventilator‑associated pneumonia: effective against pathogens colonising the respiratory tract of ventilated patients. - Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. - Severe sepsis and septic shock: used as part of empiric therapy for life‑threatening systemic infections.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Headache: transient cranial discomfort. - Infusion site phlebitis: redness or pain at the injection site. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute hypersensitivity reaction requiring emergency care. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: worsening kidney function in susceptible individuals. - Hepatic failure: rare but potentially life‑threatening liver injury.

Careful assessment and monitoring are essential when using Meropenem intravenously. - Renal function assessment: evaluate creatinine clearance before initiating therapy. - Dose adjustment in renal impairment: modify dosing intervals based on renal function. - Seizure risk monitoring: avoid in patients with a history of seizures or CNS disorders. - Confirm bacterial infection: use only for documented or strongly suspected bacterial infections. - Hypersensitivity check: do not administer to patients with known carbapenem allergy. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concurrent use can reduce valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity risk. - Other carbapenems: combined use can lead to additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: concurrent nephrotoxic potential requires renal function monitoring. - Loop diuretics: may exacerbate renal impairment when used together. - Warfarin: monitor INR as meropenem can affect anticoagulant control. - Oral contraceptives: possible reduction in contraceptive effectiveness; advise alternative methods. - NSAIDs: combined use may increase risk of renal dysfunction.